Japan's tuberculosis treatment market is estimated at approximately $466.57 million as of 2025 and is expected to grow to approximately $745.64 million by 2035. Growth is being driven by population aging, rising demand for diagnosis and the increasing adoption of rapid diagnostic testing.
Japan's tuberculosis treatment market is estimated at approximately $466.57 million as of 2025 and is projected to expand to approximately $745.64 million by 2035. The market is expected to grow at a compound annual growth rate of 4.8%, with key growth drivers including increased susceptibility to tuberculosis associated with population aging, rising demand for diagnosis, the need for prolonged treatment, and the increasing adoption of rapid diagnostic testing and molecular tests. Strengthened public health measures will also support the market.
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. It primarily affects the lungs but can also affect extrapulmonary organs. Treatment requires the use of multiple drugs in combination for several months, and inadequate treatment can lead to drug resistance, making consistent management from diagnosis through treatment adherence essential.
Population aging is a particularly important factor in the Japanese market, with growing demand for early detection, treatment initiation and medication management in light of the risk of reactivation among older people. Measures to address and monitor latent tuberculosis, as well as active tuberculosis, are expected to remain central to the market.
Treatment is centered on first-line therapies, while new drugs play an important role in treating multidrug-resistant tuberculosis. Deltyba (delamanid) and bedaquiline (Sirturo), among others, are mentioned in the context of multidrug-resistant tuberculosis treatment, while short-course regimens using rifapentine are also being considered for latent tuberculosis.